Literature DB >> 16138360

Confidence intervals for an exposure adjusted incidence rate difference with applications to clinical trials.

G Frank Liu1, Junyuan Wang, Kenneth Liu, Duane B Snavely.   

Abstract

To summarize safety data such as clinical adverse experiences in clinical trials with a moderate to long-term follow-up, we may use a measurement which accounts for the potential differences in the follow-up duration between treatment groups. The incidence rate, which uses the total person-time follow-up in a treatment group as the denominator, is one of these measures. When treatment comparisons are based on the difference of the incidence rates, it is of interest to construct confidence intervals for the rate differences. In this paper, we first discuss the assumptions and scenarios in which the exposure adjusted incidence rate may be appropriate. Then we review several methods of calculating confidence intervals for the difference of two incidence rates assuming that the number of events come from a Poisson distribution. The methods considered include Wald's method, the two-by-two table method, the Miettinen and Nurminen (MN) method, and the conditional MN method. For all but the MN method, explicit confidence intervals can be obtained. For the MN method, some numerical iterations are required. The properties of these methods are evaluated by simulations. The results show that the MN method outperforms the other three in terms of the coverage of the confidence interval, especially when the rates and therefore the number of events are small. Lastly, data from a clinical study are used to demonstrate the application of the methods.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16138360     DOI: 10.1002/sim.2335

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  14 in total

1.  Evaluating the performance of simultaneous stepwise confidence intervals for the difference between two Poisson rates.

Authors:  Brianna C Bright; Julia N Soulakova
Journal:  Commun Stat Simul Comput       Date:  2014-08-01       Impact factor: 1.118

2.  The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study.

Authors:  Samuel Frank; Claudia Testa; Mary C Edmondson; Jody Goldstein; Elise Kayson; Blair R Leavitt; David Oakes; Christine O'Neill; Christina Vaughan; Jacquelyn Whaley; Nicholas Gross; Mark Forrest Gordon; Juha-Matti Savola
Journal:  CNS Drugs       Date:  2022-10-15       Impact factor: 6.497

3.  Assessment of falls in older patients treated with duloxetine: a secondary analysis of a 24-week randomized, placebo-controlled trial.

Authors:  J Craig Nelson; Tina M M Oakes; Peng Liu; Jonna Ahl; Mark E Bangs; Joel Raskin; David G Perahia; Michael J Robinson
Journal:  Prim Care Companion CNS Disord       Date:  2012-01-03

4.  Prevalence, incidence, and residual risks for transfusion-transmitted human immunodeficiency virus Types 1 and 2 infection among Chinese blood donors.

Authors:  Jingxing Wang; Jing Liu; Fuzhu Yao; Guoxin Wen; Julin Li; Yi Huang; Yunlai Lü; Xiuqiong Wen; David Wright; Qilu Yu; Nan Guo; Paul Ness; Hua Shan
Journal:  Transfusion       Date:  2012-11-01       Impact factor: 3.157

5.  Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients.

Authors:  Josef S Smolen; Ronald van Vollenhoven; Arthur Kavanaugh; Vibeke Strand; Jiri Vencovsky; Michael Schiff; Robert Landewé; Boulos Haraoui; Catherine Arendt; Irina Mountian; David Carter; Désirée van der Heijde
Journal:  Arthritis Res Ther       Date:  2015-09-10       Impact factor: 5.156

6.  Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.

Authors:  Eva Havrdova; Douglas L Arnold; Jeffrey A Cohen; Hans-Peter Hartung; Edward J Fox; Gavin Giovannoni; Sven Schippling; Krzysztof W Selmaj; Anthony Traboulsee; D Alastair S Compston; David H Margolin; Karthinathan Thangavelu; Claudio E Rodriguez; Darlene Jody; Richard J Hogan; Panos Xenopoulos; Michael A Panzara; Alasdair J Coles
Journal:  Neurology       Date:  2017-08-23       Impact factor: 9.910

7.  Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.

Authors:  Alasdair J Coles; Jeffrey A Cohen; Edward J Fox; Gavin Giovannoni; Hans-Peter Hartung; Eva Havrdova; Sven Schippling; Krzysztof W Selmaj; Anthony Traboulsee; D Alastair S Compston; David H Margolin; Karthinathan Thangavelu; Madalina C Chirieac; Darlene Jody; Panos Xenopoulos; Richard J Hogan; Michael A Panzara; Douglas L Arnold
Journal:  Neurology       Date:  2017-08-23       Impact factor: 9.910

8.  Intake of whole grain foods and risk of type 2 diabetes: results from three prospective cohort studies.

Authors:  Yang Hu; Ming Ding; Laura Sampson; Walter C Willett; JoAnn E Manson; Molin Wang; Bernard Rosner; Frank B Hu; Qi Sun
Journal:  BMJ       Date:  2020-07-08

Review 9.  Calculation of NNTs in RCTs with time-to-event outcomes: a literature review.

Authors:  Mandy Hildebrandt; Elke Vervölgyi; Ralf Bender
Journal:  BMC Med Res Methodol       Date:  2009-03-20       Impact factor: 4.615

10.  Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study.

Authors:  Rebecca A Noel; Daniel K Braun; Ruth E Patterson; Gary L Bloomgren
Journal:  Diabetes Care       Date:  2009-02-10       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.